{
    "clinical_study": {
        "@rank": "121077", 
        "acronym": "PREVENT", 
        "arm_group": {
            "arm_group_label": "breast cancer patients", 
            "description": "Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus."
        }, 
        "biospec_descr": {
            "textblock": "whole blood, serum, skin biopsies, broncho-alveolar lavage fluid"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The investigators will determine which factors are predictive for the development and\n      severity of everolimus-induced interstitial lung disease and will develop a prediction model\n      based on these risk factors."
        }, 
        "brief_title": "Prediction of Everolimus-induced Interstitial Lung Disease", 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Lung Diseases", 
                "Lung Diseases, Interstitial"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study the investigators will prospectively investigate pulmonary adverse events\n      during treatment with everolimus. The investigators will distinguish the following\n      everolimus-induced pulmonary adverse events: pulmonary infection, everolimus-induced airway\n      disease and everolimus-induced interstitial lung disease (ILD). The investigators will\n      investigate the predictive value of pneumoproteins, everolimus exposure, pulmonary function\n      tests, four distinct radiological patterns, baseline patient characteristics and the\n      development of skin toxicity or oral mucositis for the development and severity of\n      everolimus-induced ILD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult women with metastatic or locally advanced breast cancer not amenable to\n             curative treatment by surgery or radiotherapy.\n\n          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast\n             cancer\n\n          -  Postmenopausal women\n\n          -  Radiological or clinical evidence of recurrence or progression on last systemic\n             therapy prior to enrollment\n\n          -  Resistance to treatment with a non-steroidal aromatase inhibitor\n\n          -  Serum platelets \u2265 100x10E9/l\n\n          -  Everolimus dose adjustment is recommended for patients with hepatic impairment\n             (Child-Pugh A/B/C)\n\n          -  Performance status ECOG 0 - 2 (Karnofsky index: 60 - 100)\n\n        Exclusion Criteria:\n\n          -  Patients with a HER2-overexpressing tumor\n\n          -  Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).\n\n          -  Patients with a known history of HIV seropositivity or hepatitis B or C\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Impairment of gastrointestinal function or gastrointestinal disease that may\n             significantly alter the absorption of study drugs (e.g., ulcerative disease,\n             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)\n\n          -  Patients being treated with drugs recognized as being strong inhibitors or inducers\n             of the isoenzyme CYP3A"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose\n        disease is refractory to non steroidal aromatase inhibitors, and are eligible for\n        treatment with exemestane and everolimus."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978171", 
            "org_study_id": "UMCNONCO201302"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast neoplasms", 
            "everolimus", 
            "interstitial lung disease", 
            "pneumonitis"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands"
                }, 
                "name": "Radboud university medical center"
            }, 
            "investigator": {
                "last_name": "Carla van Herpen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity", 
        "overall_contact": {
            "email": "carla.vanherpen@radboudumc.nl", 
            "last_name": "Carla van Herpen, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "annelieke.willemsen@radboudumc.nl", 
            "last_name": "Annelieke Willemsen, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Radboud university medical center, department of medical oncology", 
                "last_name": "Carla van Herpen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud university medical center, department of Pharmacy", 
                "last_name": "Nielka van Erp, PharmD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Find the correlation between:\npneumoproteins\neverolimus exposure\npulmonary function tests\nfour distinct radiological patterns of 1.0mm CT slices of the lungs\nbaseline patient characteristics\nthe development and grade of everolimus-induced skin toxicity and oral mucositis\nand the development and grade of everolimus-induced ILD", 
            "measure": "predictive factors of everolimus-induced ILD", 
            "safety_issue": "Yes", 
            "time_frame": "six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyze the temporal relationship between a decrease in pulmonary function or the occurrence of new radiological pulmonary abnormalities and an increase in the level of pneumoproteins", 
                "measure": "temporal relation pneumoproteins and ILD", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }, 
            {
                "description": "Investigate which immunological changes (cytokines, T-cells, dendritic cells) are observed in peripheral blood, skin biopsies and bronchoalveolar lavage fluid of patients with everolimus-induced toxicity", 
                "measure": "pathophysiology of everolimus-induced ILD", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }, 
            {
                "description": "Define the correlation between everolimus-induced ILD on the one hand and everolimus exposure (as per AUC0-24h) on day 14) and outcome (time to progression, as determined by treating physician) on the other hand", 
                "measure": "relation ILD and exposure and outcome", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}